Publication | Open Access

Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease

Pompe DiseaseAutoimmune DiseaseDisease MechanismImmunodeficienciesImmunologySerologic TestingPathologyRapid ReductionTherapeutic EfficacyAutoimmunityAntibody ScreeningAntibody EngineeringTherapeutic ProteinImmunotherapyMedicineLysosomal Storage Disease